Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations

Autor: Pilar Blanco Lobo, Paloma Guisado-Hernández, Isabel Villaoslada, Beatriz de Felipe, Carmen Carreras, Hector Rodriguez, Begoña Carazo-Gallego, Ana Méndez-Echevarria, José Manuel Lucena, Pilar Ortiz Aljaro, María José Castro, José Francisco Noguera-Uclés, Joshua D. Milner, Katelyn McCann, Ofer Zimmerman, Alexandra F. Freeman, Michail S. Lionakis, Steven M. Holland, Olaf Neth, Peter Olbrich

Publikováno v: JOURNAL OF CLINICAL IMMUNOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

[Purpose] STAT1 gain-of-function (GOF) and dominant-negative (DN) STAT3 syndromes share clinical manifestations including infectious and inflammatory manifestations. Targeted treatment with Janus-kinase (JAK) inhibitors shows promising results in tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ddba73a8a5b8fb0a8970e12e82b3de
https://doi.org/10.1007/s10875-022-01273-x